Dacomitinib
Brand Names: Vizimpro
Methodology & AI Transparency ⓘ
Dacomitinib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage vizimpro: is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test .
- 2 Real-world patient consensus: 76% patient "Worth It" rating across 12 anonymous logs for Dacomitinib (RxNorm 2058915).
- 3 Typical cash cost range: 30-day cash pricing ranges from $57.91 discount cash to $141.88 walk-in retail (NADAC $1.2200/unit).
- 4 Top reported side effects / signs: Most commonly reported Dacomitinib tolerability events: diarrhea (8.3%), cutaneous rash (2.9%), pruritus (3.2%).
Ask our AI Specialists anything about Dacomitinib
Dacomitinib Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage vizimpro: is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )
12.1 Mechanism of Action Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. Dacomitinib demonstrated dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in mice bearing subcutaneously implanted human tumor xenografts driven by HER family targets including mutated EGFR.
With Biphasic clearance with 5–9 hr terminal t½ under Dacomitinib maintenance residence kinetics and Systemic oral bioavailability of roughly 54%–66% following first-pass transit bioavailability, Dacomitinib undergoes primary cyp2d6 cytochrome processing paired with glucuronide elimination for dacomitinib and establishes therapeutic activity over initial pharmacodynamic onset within 1–4 hrs (peak cmax) for dacomitinib.
Standard adult regimens span 45 mg/1 Tablet, Film Coated, 15 mg/1 Tablet, Film Coated, 30 mg/1 Tablet, Film Coated. Prescribers screen specifically against known hypersensitivity to dacomitinib or structurally related fda prescription therapeutic agent compounds; concomitant contra-labeled cyp/transporter therapies during active dacomitinib administration, while community micro-logs most frequently note diarrhea (8.3% of reports), nausea (7.3% of reports), cough (6.6% of reports).
Potent CYP2D6 modulators alter hepatic clearance of Dacomitinib, shifting steady-state plasma concentrations.
Avoid overlapping fda prescription therapeutic agent prescriptions alongside Dacomitinib to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Dacomitinib or structurally related fda prescription therapeutic agent compounds
- Concomitant contra-labeled CYP/transporter therapies during active Dacomitinib administration
Logged Side-Effect Incidence (12 Reports)
Dacomitinib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dacomitinib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Patient's perspective on treatment with dacomitinib: patient-reported outcomes: What a 448-Participant Study Found There were no clinically meaningful changes in functioning and overall QoL in either treatment group. Future oncology (London, England) • 2021-03-15 • Phase III Randomized Trial | N = 448 | 87/100 | PMID 33164569 ↗ |
Dacomitinib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.2200/unit (~$36.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $141.88 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $57.91 / mo | View logs ↓ |
Dacomitinib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dacomitinib RxNorm Concept ID | 2058915 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.2200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $141.88 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $57.91 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dacomitinib Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Dacomitinib integrating DailyMed SPL (2026-06-23), CMS NADAC ($1.2200/unit), and 12 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dacomitinib community threads and patient logs by age, biological sex, dosage, and treatment duration.